Faculty

Research

Systems

Infrastructure

Patient & Public Awareness

Working with Industry

Research Databases

About Us

News: £12 million further investment following results from successful NIHR Oxford Biomedical Research Centre supported trial of gene therapy for form of blindness

Title

£12 million further investment following results from successful NIHR Oxford Biomedical Research Centre supported trial of gene therapy for form of blindness 

News Title

£12 million further investment following results from successful NIHR Oxford Biomedical Research Centre supported trial of gene therapy for form of blindness 

News Content

Nightstar, a new spin-out company from the University of Oxford and its research commercialisation company Isis Innovation, is to receive a £12 million investment from Syncona, an independent subsidiary of the Wellcome Trust.

The company has been formed to develop and commercialise therapies for retinal dystrophies – degenerative conditions that affect vision.

The announcement follows promising results earlier this month from the first clinical trial of a gene therapy for an inherited form of progressive blindness called choroideremia.

The gene therapy for choroideremia is currently being studied in a 12 patient Phase I clinical trial, supported by the Health Innovation Challenge Fund, a partnership between the Wellcome Trust and the Department of Health.

The research has received additional support from the NIHR Oxford Biomedical Research Centre and the charity Fight for Sight. Plans for an independent, grant-funded Phase II study are already underway.

News Link

Read the full press release 

News Date

31/01/2014 

Expires

30/04/2014 

Date Created

 

Date Modified

 
Attachments
Created at 31/01/2014 09:43  by Vaishali Patel 
Last modified at 31/01/2014 09:43  by Vaishali Patel